Guideline Updated for Managing Hyperbilirubinemia in Newborns
All families should receive written and verbal education about neonatal jaundice before discharge
All families should receive written and verbal education about neonatal jaundice before discharge
Stay up-to-date on the latest drugs in development.
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system.
Stay up-to-date on the latest drugs in development.
Mosunetuzumab is a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
The new ProvayBlue presentation is supplied in a box of five 10mL single-dose vials; each vial contains 50mg of methylene blue.
Patients with rs2814778-CC also have lower last leukocyte count and lower dosing; findings persist after adjustment for race
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.